AzTrials
AzTrials

Atrial Fibrillation (AF)FOLLOW-AFNCT07471308

P-wave Duration and Local Potential as Predictors of AF Recurrence Following Pulmonary Vein Isolation

An observational study of Atrial Fibrillation (AF) and Atrial Fibrillation Patients Treated With the FARAPULSE™ PFA System, run by CathVision ApS at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia worldwide and is associated with substantial morbidity, mortality, and healthcare utilization. Catheter ablation, most commonly pulmonary vein isolation (PVI), is an established rhythm control strategy for AF4. Read more about this study

Who is it for?
Ages 21 years and older
What is being tested?
AF Recurrence RIsk Assessment post pulmonary vein isolation
Type of treatment
Medical device
How many people
300 participants
Where
1 siteUnited States
Study dates
13 Apr 2026to 15 Nov 2026
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Outpatient EHR

Who may be able to join

  • Age ≥ 21 years
  • Paroxysmal or persistent atrial fibrillation
  • Underwent pulmonary vein isolation using pulse field ablation
  • Patient record with pre-/post-ablation 12-lead ECGs and intra-procedural unipolar electrograms

Who cannot join

  • Incomplete patient record:
  • Lack of 12-leads ECG recording or intracardiac electrograms
  • Lack of post-procedure follow-up assessment
  • Follow-up was less than 6 months
  • Cardiac recording data incomplete or not of sufficient quality
  • Cardiac anatomical variation such as Left Common, or Right Accessory

Trial locations and contacts

1 site in 1 country.

United States1 site
  • The Valley Hospital

    Paramus, New Jersey, 07652

Other trials in United States

About this study

Official title: Validation of an Algorithm Designed to Predict the Recurrence of AF After Pulmonary Vein Isolation Using P-wave Duration and Procedural Unipolar Atrial Local Potential Measurements

Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia worldwide and is associated with substantial morbidity, mortality, and healthcare utilization. Catheter ablation, most commonly pulmonary vein isolation (PVI), is an established rhythm control strategy for AF4.

Despite technological advances and the emergence of pulse field ablation (PFA), long-term AF recurrence after a first ablation procedure remains frequent, occurring in approximately 30-50% of patients5. Post-ablation follow-up strategies, including visit frequency, rhythm monitoring intensity, and Antiarrhythmic Drug management, vary widely across providers and institutions and are largely guided by subjective assessment rather than objective, science-based recurrence risk estimation6. In parallel, asymptomatic (silent) AF recurrence is exacerbated following ablation, limiting the reliability of symptom-driven follow-up7.

Read more

FOLLOW-AF is a retrospective, observational cohort study designed to validate the FollowGenius algorithm and evaluate the diagnostic performance in predicting AF recurrence based on atrial remodeling and vein isolation.

The cohort will be patients with paroxysmal or persistent AF who underwent PVI with the PFA modality.

Read the detailed description

Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia worldwide and is associated with substantial morbidity, mortality, and healthcare utilization.3 Catheter ablation, most commonly pulmonary vein isolation (PVI), is an established rhythm control strategy for symptomatic AF.4 Historically, this has been achieved using radiofrequency and thermal energy. However, more recently a new energy source known as pulsed field ablation (PFA) has been introduced. As PFA is tissue selective, it preserves the function of nearby structures such as the esophagus and phrenic nerve making it safer to use. As PFA is delivered in short bursts of high energy, it is also more efficient and leads to shorter procedures.

Despite technological advances and the emergence of pulse field ablation (PFA), long-term AF recurrence after a first ablation procedure remains frequent, occurring in approximately 30-50% of patients.5 Post-ablation follow-up strategies, including visit frequency, rhythm monitoring intensity, and anticoagulation management, vary widely across providers and institutions and are largely guided by subjective assessment rather than objective, science-based recurrence risk estimation.6 In parallel, asymptomatic (silent) AF recurrence is exacerbated following ablation, limiting the reliability of symptom-driven follow-up.7

The underlying causes of AF recurrence are broadly driven by two distinct, yet complementary, mechanisms:

  1. Atrial Substrate Modification (Remodeling): Many patients have pre-existing atrial myopathy or remodeling due to long-standing hypertension, heart failure, or AF itself. This "diseased substrate" is prone to initiating and sustaining new AF triggers outside the pulmonary veins. P-wave duration, a simple, non-invasive marker from the surface ECG, is a well-established surrogate for this electrical and structural remodeling.2,9,10
  2. PVI Isolation (Reconnection): The primary goal of ablation is to create durable, transmural lesions to isolate the pulmonary veins. If lesions are incomplete, electrical reconnection often occurs, allowing the original AF triggers to re-initiate arrhythmia. Residual local potentials measured during the ablation procedure are a suggested marker of incomplete lesion formation, predicting non-durability.1,11,12

Pulmonary vein isolation status is acquired by measuring the intra-cardiac residual electrical activity (local potential) in the vein, after PFA application. Residual local potentials will be extracted by the PF Analyzer module of the ECGenius™ System. Isolation status is defined based on thresholds from literature.

The FollowGenius algorithm is intended to allow AF recurrence risk stratification by providing risk scores (0-100).

FOLLOW-AF is a retrospective, observational cohort study designed to validate the prediction algorithm and evaluate the diagnostic performance in predicting AF recurrence based on atrial remodeling and vein isolation.

The cohort will be patients with paroxysmal or persistent AF who underwent PVI with the PFA modality.

Being tested
AF Recurrence RIsk Assessment post pulmonary vein isolation
Keywords
PVI, PFA, AF, electrophysiology, cardiac ablation, catheter, atrial fibrillation
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AF Recurrence RIsk Assessment post pulmonary vein isolationDevice

    AF Recurrence RIsk Assessment post pulmonary vein isolation based on PWD and Residual Local Potentials

Study groups in NCT07471308
Study groupRoleWhat they receive
Cohort 1 - Continuous monitoringSubject with continuous post-procedure monitoring, such as ILR, pacemaker, and CRT device
Receives: Device: AF Recurrence RIsk Assessment post pulmonary vein isolation
Cohort 2 - Transient monitoringSubject with transient monitoring, such as Holter, and tracking devices
Receives: Device: AF Recurrence RIsk Assessment post pulmonary vein isolation
Cohort 3 - Punctual monitoringSubject with punctual monitoring, such as reported symptoms during physician visit
Receives: Device: AF Recurrence RIsk Assessment post pulmonary vein isolation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary Objective

    Evaluate predictive performance of a novel prognostic algorithm (called FollowGenius) combining p-wave duration and procedural unipolar atrial local potential measurements in predicting recurrence of AF after pulmonary vein isolation using PFA.

    Measured: 6 months

Secondary outcomes (1)
  1. Secondary Objective

    Evaluate agreement between predicted risk and observed recurrence. Evaluate agreement between predicted risk and post-procedural AF burden. Evaluate contribution (weighting) of each individual predictors in AF recurrence risk score.

    Evaluate correlation of performance across different sub-group (paroxysmal vs persistent AF, first vs redo ablation, sex, age bands, monitoring modality)

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2026
  2. Study start13 Apr 2026
  3. Primary completion31 Aug 2026
  4. Study completion15 Nov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07471308
Sponsor's protocol ID
CVFOLLOW-001
Acronym
FOLLOW-AF
Status last verified
Oct 2026
First submitted
10 Mar 2026
Last updated
20 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in